Ok, if you're just getting up and want to understand what is going on, this is a post from Reddit
I Just Read the ESMO Abstract — Here’s What It Means (Plain English). Share This. ????
If you’ve ever held a single share of CYDY...
If you’ve ever told someone, “I think they’ve got something”...
If you’ve ever said, “Just wait — the data will come”...
It just did.
???? What Was Released
CytoDyn just published breast cancer data through ESMO — one of the most respected oncology conferences in the world.
They studied 28 women with stage 4 triple-negative breast cancer — the deadliest kind.
These weren’t early-stage cases.
Most had failed 3 or 4 treatments. Some had brain tumors.
They were out of options.
This was last-chance medicine.
???? What Happened?
1-year survival: 41%
2-year: 25%
3-year: 20%
(For comparison: most drugs in this space barely hit 25% at 1 year.
By year 3? Almost nobody’s left.)
But then came the shock:
Four women are still alive.
Not just alive — completely cancer-free.
3.5 to 4+ years later.
Let that hit.
They were done.
Leronlimab wasn’t supposed to cure anyone — just maybe buy time.
Instead, it may have saved them.
???? Why This Is Massive
This isn’t a rumor.
This isn’t a press release.
This is peer-reviewed survival data — published and now on record.
It’s proof that Leronlimab may be doing something no other drug has ever done in this cancer.
???? And This Was Just the Trailer...
This was just the abstract.
The full poster presentation drops May 15.
That’s when we’ll likely see:
How it worked
Who it worked best on
And where it’s going next — new trials, FDA talks, maybe even a partner
???? What Happens Now?
Right now? It’s quiet.
No news alert.
No Wall Street hype.
Just buried gold in a European conference database.
But make no mistake:
This is the strongest data CytoDyn has ever published.
This is the moment long-term believers waited years for.
And when the world catches up?
This won’t be a penny stock.
It’ll be a biotech comeback story people talk about for a decade.
???? Share This.
Send it to your group chats.
Post it in your Discord.
Email it to that guy who said CYDY was a joke.
Because you don’t get 4+ year survival and no evidence of disease in stage 4 triple-negative breast cancer.
Not like this.
Not without something extraordinary.
And now?
It’s public.
We’re not early anymore. We’re at the turn.
Let them laugh today.
Let them doubt.
We just saw the first real proof that Leronlimab can change lives.
And the world is about to find out.
I Just Read the ESMO Abstract — Here’s What It Means (Plain English). Share This. ????
If you’ve ever held a single share of CYDY...
If you’ve ever told someone, “I think they’ve got something”...
If you’ve ever said, “Just wait — the data will come”...
It just did.
???? What Was Released
CytoDyn just published breast cancer data through ESMO — one of the most respected oncology conferences in the world.
They studied 28 women with stage 4 triple-negative breast cancer — the deadliest kind.
These weren’t early-stage cases.
Most had failed 3 or 4 treatments. Some had brain tumors.
They were out of options.
This was last-chance medicine.
???? What Happened?
1-year survival: 41%
2-year: 25%
3-year: 20%
(For comparison: most drugs in this space barely hit 25% at 1 year.
By year 3? Almost nobody’s left.)
But then came the shock:
Four women are still alive.
Not just alive — completely cancer-free.
3.5 to 4+ years later.
Let that hit.
They were done.
Leronlimab wasn’t supposed to cure anyone — just maybe buy time.
Instead, it may have saved them.
???? Why This Is Massive
This isn’t a rumor.
This isn’t a press release.
This is peer-reviewed survival data — published and now on record.
It’s proof that Leronlimab may be doing something no other drug has ever done in this cancer.
???? And This Was Just the Trailer...
This was just the abstract.
The full poster presentation drops May 15.
That’s when we’ll likely see:
How it worked
Who it worked best on
And where it’s going next — new trials, FDA talks, maybe even a partner
???? What Happens Now?
Right now? It’s quiet.
No news alert.
No Wall Street hype.
Just buried gold in a European conference database.
But make no mistake:
This is the strongest data CytoDyn has ever published.
This is the moment long-term believers waited years for.
And when the world catches up?
This won’t be a penny stock.
It’ll be a biotech comeback story people talk about for a decade.
???? Share This.
Send it to your group chats.
Post it in your Discord.
Email it to that guy who said CYDY was a joke.
Because you don’t get 4+ year survival and no evidence of disease in stage 4 triple-negative breast cancer.
Not like this.
Not without something extraordinary.
And now?
It’s public.
We’re not early anymore. We’re at the turn.
Let them laugh today.
Let them doubt.
We just saw the first real proof that Leronlimab can change lives.
And the world is about to find out.
10
